Clearly, a better insight into the interaction between DDR and tumor immunity is required in the future, as well as exploration of the optimal combination of DDR inhibitors with immunotherapy and radiotherapy to improve the clinical outcomes of conventional therapies and increase the therapeutic benefit for CRC patients. This evidence concerns the gene DDR1 and colorectal carcinoma.